PRKN and cancer: Our observation that the PARK2 promoter is heavily methylated in certain tumors in vivo, correlating with worse patient outcome, points to epigenetic silencing as one of the mechanisms for PRKN loss in cancer, compounding other examples of genetic inactivation (51).